For a review, it was determined that since the introduction of angiotensin-converting enzyme inhibitors (ACEIs) in the 1980s for the treatment of hypertension and congestive heart failure, there had been a gradual increase in use owing to these and other additional indications. That has resulted in a concurrent increase in the number of side effects caused by ACEIs, primarily angioedema of varying severity. According to much research, ACEI-induced angioedema was related to high levels of bradykinin of various origins, and it happened preferentially in females and African-American populations. Because of the varying latency period following treatment beginning, diagnosing ACEI-induced angioedema was analyzed to be problematic. Other causes of angioedema must be investigated in the differential diagnosis. The therapy of ACEI-induced angioedema entailed discontinuing the causative substance and treating the response with various treatments according to its severity. Angiotensin II receptor blockers (ARBs) had been demonstrated in certain trials to be an option, albeit 10% of individuals with ACEI-associated angioedema experienced angioedema episodes after taking an ARB. As a result, ARBs were reserved for individuals with a strong therapeutic requirement for angiotensin-converting enzyme inhibition.

Researchers concentrated on current and important elements of angioedema caused by ACEIs. There was a discussion of the pathogenic mechanism, epidemiology and risk factors, differential diagnosis, patient management, and therapy.